The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Christopher J. Hawkey

Institute of Clinical Research

Wolfson Digestive Diseases Centre

University Hospital




Name/email consistency: high



  • Institute of Clinical Research, Wolfson Digestive Diseases Centre, University Hospital, Nottingham, UK. 2004 - 2009
  • University Hospital, Nottingham, Canada. 1999 - 2004
  • Wolfson Digestive Diseases Centre, Institute of Clinical Research, Nottingham University, University Hospital, UK. 2004
  • University Hospital Nottingham, Nottingham, United Kingdom. 2004
  • Division of Gastroenterology, University Hospital, Nottingham, UK. 1998 - 2003
  • Division of Gastroenterology, University Hospital Nottingham, Queen's Medical Centre, Nottingham, England. 2000


  1. Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies. Hawkey, C.J., Svedberg, L.E., Naesdal, J., Byrne, C. Clin. Drug. Investig (2009) [Pubmed]
  2. NSAIDs and aspirin: notorious or FAMOUS?. Hawkey, C.J. Lancet (2009) [Pubmed]
  3. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial. Hawkey, C.J., Weinstein, W.M., Stricker, K., Murphy, V., Richard, D., Krammer, G., Rebuli, R. Aliment. Pharmacol. Ther. (2008) [Pubmed]
  4. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Hawkey, C.J., Ell, C., Simon, B., Albert, J., Keuchel, M., McAlindon, M., Fortun, P., Schumann, S., Bolten, W., Shonde, A., Hugot, J.L., Yu, V., Arulmani, U., Krammer, G., Rebuli, R., Toth, E. Clin. Gastroenterol. Hepatol. (2008) [Pubmed]
  5. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Hawkey, C.J., Weinstein, W.M., Smalley, W., Gitton, X., Sallstig, P., Stricker, K., Krammer, G., Mellein, B., Richard, D., Matchaba, P. Gastroenterology (2007) [Pubmed]
  6. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Hawkey, C.J., Jones, R.H., Yeomans, N.D., Scheiman, J.M., Talley, N.J., Goldstein, J.L., Ahlbom, H., Naesdal, J. Aliment. Pharmacol. Ther. (2007) [Pubmed]
  7. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Hawkey, C.J., Talley, N.J., Scheiman, J.M., Jones, R.H., Långström, G., Naesdal, J., Yeomans, N.D. Arthritis Res. Ther. (2007) [Pubmed]
  8. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Hawkey, C.J., Gitton, X., Hoexter, G., Richard, D., Weinstein, W.M. Clin. Gastroenterol. Hepatol. (2006) [Pubmed]
  9. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Hawkey, C.J., Hawkey, G.M., Everitt, S., Skelly, M.M., Stack, W.A., Gray, D. Br. J. Clin. Pharmacol (2006) [Pubmed]
  10. NSAIDs, coxibs, and the intestine. Hawkey, C.J. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  11. COX-2 chronology. Hawkey, C.J. Gut (2005) [Pubmed]
  12. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. Hawkey, C.J., Farkouh, M., Gitton, X., Ehrsam, E., Huels, J., Richardson, P. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  13. Stem cell transplantation for Crohn's disease. Hawkey, C.J. Best. Pract. Res. Clin. Haematol (2004) [Pubmed]
  14. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?. Hawkey, C.J. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  15. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. Hawkey, C.C., Svoboda, P., Fiedorowicz-Fabrycy, I.F., Nasonov, E.L., Pikhlak, E.G., Cousin, M., Gitton, X., Hoexter, G. J. Rheumatol. (2004) [Pubmed]
  16. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Hawkey, C.J., Langman, M.J. Gut (2003) [Pubmed]
  17. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Hawkey, C.J., Atherton, J.C., Treichel, H.C., Thjodleifsson, B., Ravic, M. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  18. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Hawkey, C.J., Laine, L., Simon, T., Quan, H., Shingo, S., Evans, J. Gut (2003) [Pubmed]
  19. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Hawkey, C.J., Jones, J.I., Atherton, C.T., Skelly, M.M., Bebb, J.R., Fagerholm, U., Jonzon, B., Karlsson, P., Bjarnason, I.T. Gut (2003) [Pubmed]
  20. Gastrointestinal safety of selective COX-2 inhibitors. Hawkey, C.J., Skelly, M.M. Curr. Pharm. Des. (2002) [Pubmed]
  21. Cyclooxygenase inhibition: between the devil and the deep blue sea. Hawkey, C.J. Gut (2002) [Pubmed]
  22. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Hawkey, C.J., Jackson, L., Harper, S.E., Simon, T.J., Mortensen, E., Lines, C.R. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  23. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Hawkey, C.J., Laine, L., Harper, S.E., Quan, H.U., Bolognese, J.A., Mortensen, E. Aliment. Pharmacol. Ther. (2001) [Pubmed]
  24. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Cullen, D.J., Seager, J.M., Holmes, S., Doherty, M., Wilson, J.V., Garrud, P., Garner, S., Maynard, A., Logan, R.F., Hawkey, C.J. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  25. Ibuprofen versus other non-steroidal anti-inflammatory drugs: use in general practice and patient perception. Seager, J.M., Cullen, D.J., Pearson, G., Holmes, S., Doherty, M., Wilson, J.V., Garrud, P., Garner, S., Maynard, A., Logan, R.F., Hawkey, C.J. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  26. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Hawkey, C.J. Gut (2000) [Pubmed]
  27. Stem cell transplantation for inflammatory bowel disease: practical and ethical issues. Hawkey, C.J., Snowden, J.A., Lobo, A., Beglinger, C., Tyndall, A. Gut (2000) [Pubmed]
  28. Outcomes studies of drug induced ulcer complications: do we need them and how should they be done?. Hawkey, C.J. BMJ (2000) [Pubmed]
  29. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?. Hawkey, C.J. Eur. J. Gastroenterol. Hepatol (2000) [Pubmed]
  30. Nonsteroidal anti-inflammatory drug gastropathy. Hawkey, C.J. Gastroenterology (2000) [Pubmed]
  31. What do we do about Helicobacter pylori?. Hawkey, C.J. Can. J. Gastroenterol. (1999) [Pubmed]
  32. Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. Hawkey, C.J. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  33. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Hawkey, C.J., Tulassay, Z., Szczepanski, L., van Rensburg, C.J., Filipowicz-Sosnowska, A., Lanas, A., Wason, C.M., Peacock, R.A., Gillon, K.R. Lancet (1998) [Pubmed]
WikiGenes - Universities